Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
13 Septiembre 2023 - 7:30AM
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage
pharmaceutical company focused on modulating lipid-signaling
pathways to develop treatments for people living with cancer, pain,
and neurological conditions, today announced that Professor Saoirse
O’Sullivan, Artelo’s Vice President of Translational Sciences, will
be presenting at the 13th Congress of the European Pain Federation
(EFIC) being held September 20-22, 2023 at the HUNGEXPO Exhibition
Centre in Budapest, Hungary.
Professor O’Sullivan’s presentation, titled,
“Effects of the FABP5 Inhibitor, ART26.12, in Oxaliplatin-Induced
Peripheral Neuropathy in Rats,” is scheduled for 6:30 a.m. ET /
12:30 p.m. CEST on Wednesday, September 20, 2023.
The Company recently announced that it has
completed a pre-IND (Investigational New Drug) meeting with the
U.S. Food and Drug Administration regarding the manufacturing,
preclinical and clinical development of ART26.12. Artelo plans to
file an IND application for the use of ART26.12 in neuropathic pain
in the first half of 2024.
To register for the event, please visit: 13th
Congress of the European Pain Federation.
About ART26.12Fatty Acid Binding
Proteins (FABPs) are a family of intracellular proteins that
chaperone lipids including endocannabinoids and fatty acids.
Various inhibitors of FABPs may be particularly useful for the
treatment of specific cancers, neuropathic and nociceptive pain,
and anxiety disorders. ART26.12, Artelo’s lead FABP inhibitor
compound, is a selective inhibitor of FABP5. While developing our
lead molecule for chemotherapy-induced peripheral neuropathy,
additional compounds from our extensive library of potent and
selective inhibitors of FABPs have been identified and selected for
advancement towards regulatory-enabling studies in cancer and other
areas of high-unmet need where inhibition of FABPs show significant
promise.
About Painful
NeuropathiesPeripheral neuropathy refers to a condition in
which there is damage to the peripheral nerves. These nerves are
responsible for transmitting signals between the central nervous
system and the rest of the body. Chemotherapy-induced
peripheral neuropathy (CIPN) is a common and often painfully
debilitating complication of cancer therapies, sometimes resulting
in reduction or cessation of treatment. No currently approved
treatment exists for CIPN. Diabetic neuropathy refers to a type of
nerve damage that occurs as a complication of diabetes. It is
caused by long-term high blood sugar levels, which can lead to
damage of the blood vessels and nerves throughout the body. The
prevalence of diabetic neuropathy is significant due to the
increasing number of people with diabetes worldwide.
About Artelo BiosciencesArtelo
Biosciences, Inc. is a clinical stage pharmaceutical company
dedicated to the development and commercialization of proprietary
therapeutics that modulate lipid-signaling pathways including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, anxiety, pain, neuropathy, and inflammation. Led by proven
biopharmaceutical executives collaborating with highly respected
researchers and technology experts, the company applies leading
edge scientific, regulatory, and commercial discipline to develop
high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and Private
Securities Litigation Reform Act, as amended, including those
relating to the Company’s product development, clinical and
regulatory timelines, market opportunity, competitive position,
possible or assumed future results of operations, business
strategies, potential growth opportunities and other statement that
are predictive in nature. These forward-looking statements are
based on current expectations, estimates, forecasts and projections
about the industry and markets in which we operate and management’s
current beliefs and assumptions. These statements may be identified
by the use of forward-looking expressions, including, but not
limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,”
“estimate,” “potential,” “predict,” “project,” “should,” “would”
and similar expressions and the negatives of those terms. These
statements relate to future events or our financial performance and
involve known and unknown risks, uncertainties, and other factors
which may cause actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Such factors include those set forth in the Company’s
filings with the Securities and Exchange Commission, including our
ability to raise additional capital in the future. Prospective
investors are cautioned not to place undue reliance on such
forward-looking statements, which speak only as of the date of this
press release. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events or otherwise, except to the extent
required by applicable securities laws.
Investor Relations
Contact:Crescendo Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Artelo Biosciences (NASDAQ:ARTL)
Gráfica de Acción Histórica
De May 2023 a May 2024